Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Curr Opin Colloid Interface Sci. 2017 Jul 28;31:30–42. doi: 10.1016/j.cocis.2017.07.003

Figure 5.

Figure 5

In vivo antitumor efficacy of HPMA copolymer-drug conjugates against A2780 human ovarian carcinoma xenografts. The dose for each injection is expressed as a dose equivalent to free drug (gemcitabine or epirubicin 5 mg/kg, paclitaxel 20 mg/kg). Tumor growth was inhibited by (A): Gemcitabine monotherapy. (B) Paclitaxel monotherapy. (C) Epirubicin monotherapy. Free drug and untreated groups were stopped on day 20 due to large size of tumors. (D) Long-term monitoring of tumor growth in conjugate treatments. (E) The tumor size on day 80 of the polymer conjugates. (F) End point photographs of tumor-bearing mice from variable treatments. (G) Characterization of the conjugates. (H) Comparison of pharmacokinetic parameters for 125I-labeled conjugates in mice. Adapted from refs. [51,54].